Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant

Bone Marrow Transplant. 2016 Sep;51(9):1253-5. doi: 10.1038/bmt.2016.104. Epub 2016 Apr 18.

Authors

M Ueda^{1

2}, M de Lima^{1

2}, P Caimi^{1

2}, B Tomlinson^{1

2}, J Little^{1

2}, R Creger^{1

2}, H Lazarus^{1

2}, B Cooper^{1

2}

Affiliations

¹ Stem Cell Transplant Program, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.
² Case Western Reserve University, Cleveland, OH, USA.

PMID: 27088374
DOI: 10.1038/bmt.2016.104

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Aged
Antibodies, Bispecific / therapeutic use*
Antineoplastic Agents / therapeutic use
Hematopoietic Stem Cell Transplantation / methods*
Humans
Lymphocyte Transfusion*
Middle Aged
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Recurrence
Transplantation, Homologous
Treatment Outcome

Substances

Antibodies, Bispecific
Antineoplastic Agents
blinatumomab